{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-005022","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.551814+00:00","generated_at":"2026-06-03T23:25:25.295177+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mustang Bio cuts workforce by 81% amid CFIUS uncertainty and facility sale to uBriGene","bullets":["Board approved ~81% workforce reduction to reduce costs and preserve capital due to fundraising environment and CFIUS review of facility sale.","Workforce reduction expected substantially complete in Q2 2024; expects ~$0.2M in one-time termination cash expenditures.","Company continues to evaluate all strategic and other alternatives related to the business.","Sale of leasehold interest and assets to uBriGene (Chinese CDMO) pending CFIUS review; terms not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-005022","json":"https://secwatch.observer/filing/0001558370-24-005022.json","markdown":"https://secwatch.observer/filing/0001558370-24-005022.md","text":"https://secwatch.observer/filing/0001558370-24-005022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000155837024005022/0001558370-24-005022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000155837024005022/tmb-20240410x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:25:25.295177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7dd57945e589ab7b5e308c31bdc8df5f31b8cb1c","claim":"MUSTANG BIO, INC. announced a restructuring with charges of approximately $0.2 million (approximately 81% of its employee base).","evidence_excerpt":"to be substantially completed in the second quarter of 2024. As a result of these actions, Mustang expects to incur personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which are expected to be incurred in the second quarter of 2024. Mustang may also incur other charges or cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000155837024005022/0001558370-24-005022-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.2 million"},{"label":"Headcount","value":"approximately 81% of its employee base"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}